Nuo Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Nuo Therapeutics, a medical device company, announced significant revenue growth in 2025 driven by its Aurix product and a new distribution agreement with Smith+Nephew, alongside securing new debt financing, despite ongoing net losses and a going concern warning.
OQB
Nuo Therapeutics reports increased revenues for 2024 and a new distribution agreement with Smith+Nephew for its Aurix product.
OQB
Nuo Therapeutics, a regenerative therapies company, reported increased product revenue in 2023 but continues to face financial challenges and going concern uncertainties.